Ym Inc.

Ym Biosciences Reports Positive Nimotuzumab Four-year Survival Data Presented At Astro 2009.(Clinical report)
Cancer Weekly; 11/17/2009; 1510 words; YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies...neck cancer patients," said David Allan, Chairman and CEO of YM BioSciences. "Activity of nimotuzumab in the BEST trial was...

YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS.
PR Newswire; 11/11/2009; 3865 words; ...Nov. 11 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company...Treasury Department cleared YM's subsidiary, YM BioSciences USA Inc., of any limitations in clinical trials...

Ym Biosciences Reports Additional Results From Nimotuzumab Phase Iii Study In Children With Glioma Presented By Oncoscience Ag.
Cancer Weekly; 11/10/2009; 981 words; YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies...Monoclonal Antibodies, Oncology, Pediatric, Pediatrics, YM BioSciences Inc. This article was prepared by Cancer Weekly editors from...

YM BioSciences Goes Public, Raises $9.74M In Placement.
BIOWORLD Today; 11/4/2009; 1004 words; ...to raise C$15million, YM BioSciences Inc. went public in two places...Mississauga, Ontario-based YM, which is still deciding...was licensed from BioStar Inc., of Saskatoon, Saskatchewan...with the human," which YM took over, Vernon said...

CancerVax Travels To Cuba To Expand Cancer Pipeline.
BIOWORLD Today; 11/3/2009; 1608 words; ...trade embargo on the communist island, and dealing with YM Biosciences Inc., a third party already involved with the Cuban firm...will deal directly with Cimab, which then will deal with YM for payments related to the two preclinical products...